Ahmad Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmad Ali has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Aizaz Anwar Khalid
Peshawar Medical College, Peshawar, Pakistan
3 shared publications - Asim Shah
Khyber Medical College, Peshawar, Pakistan
3 shared publications - Suleman Khan
Khyber Medical College Peshawar Pakistan
3 shared publications - Ali Sher Erkin
Kabul University of Medical Sciences (KUMS) Kabul Afghanistan
2 shared publications Amina Nisar
2 shared publicationsFatima Aman
Rehman Medical Institute Peshawar Pakistan
2 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (11)
Clinically Suspected Tumefactive Demyelination Mimicking a Brain Tumor in a 10‐Year‐Old Boy: A Case Report
After cranial surgery, a 10‐year‐old boy developed hand weakness, numbness, and fatigue. MRI showed frontoparietal lesions; biopsy lacked documented demyelination. Symptoms and lesions reportedly improved after methylprednisolone. Tumefactive demyelination was suspected, but discordant laterality, unavailable antibody testing, and brief follow‐up left the diagnosis unclassified.
- 6 November 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (11)
Open AccessClinically Suspected Tumefactive Demyelination Mimicking a Brain Tumor in a 10‐Year‐Old Boy: A Case Report
After cranial surgery, a 10‐year‐old boy developed hand weakness, numbness, and fatigue. MRI showed frontoparietal lesions; biopsy lacked documented demyelination. Symptoms and lesions reportedly improved after methylprednisolone. Tumefactive demyelination was suspected, but discordant laterality, unavailable antibody testing, and brief follow‐up left the diagnosis unclassified.
- Open Access
- 3 November 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (11)
Severe Plasmodium vivax Malaria Presenting With Circulatory Shock and Coagulation Abnormalities: A Case Report
Severe Plasmodium vivax malaria may cause vasopressor‐requiring shock, profound thrombocytopenia, jaundice, coagulation activation, and transient cardiopulmonary abnormalities. Early parasite confirmation and close monitoring for evolving organ dysfunction are essential.
- 3 November 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (11)
Open AccessSevere Plasmodium vivax Malaria Presenting With Circulatory Shock and Coagulation Abnormalities: A Case Report
Severe Plasmodium vivax malaria may cause vasopressor‐requiring shock, profound thrombocytopenia, jaundice, coagulation activation, and transient cardiopulmonary abnormalities. Early parasite confirmation and close monitoring for evolving organ dysfunction are essential.
- Open Access
- 4 September 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (36) , e50542
Potent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis
Background: Denosumab cessation causes rebound bone turnover, fast bone loss, and an elevated risk of vertebral fractures. Pooled data about the fracture prevention efficacy of potent bisphosphonates (BPs) as sequential therapy have been lacking to counteract this risk. Methods: This systematic review and meta-analysis was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. PubMed, Scopus, the Cochrane Library, and ClinicalTrials.gov were searched from the beginning through May 1, 2026. Included studies comprised adults with osteoporosis or low bone mass who discontinued denosumab and subsequently received potent BP therapy, defined as alendronate or zoledronic acid, compared with no subsequent antiresorptive therapy or a selective estrogen receptor modulator (SERM). Random-effects meta-analyses were performed using the Mantel–Haenszel method to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). Prespecified subgroup analyses were conducted based on comparator type. The Grading of Recommendations Assessment, Development and Evaluation assessment method was applied to assess the certainty of the evidence. Results: Six studies were included; 683 participants contributed to the primary incident vertebral fracture analysis. Potent BP therapy was linked to a considerable reduction in incident vertebral fractures (RR = 0.29; 95% CI: 0.14–0.59; 71% relative risk reduction), multiple vertebral fractures (RR = 0.08; 95% CI: 0.01–0.43; 92% relative risk reduction), and clinical vertebral fractures (RR = 0.18; 95% CI: 0.07–0.49; 82% relative risk reduction). The protective effect was driven mainly by comparisons with no subsequent therapy, while comparisons with SERM therapy were limited and not statistically significant. There was no statistically significant reduction in any fracture (RR = 0.35; 95% CI: 0.10–1.24) or non-vertebral fracture (RR = 0.43; 95% CI: 0.07–2.64). Overall certainty of evidence was low to very low, mainly due to the observational nature of most included studies and imprecision in several outcomes. Conclusion: Potent BP therapy was related to decreased vertebral fracture risk after denosumab termination, particularly when compared with no subsequent therapy. Evidence versus SERM comparators was limited and inconclusive. The results are in agreement with the present clinical guideline recommendations for sequential BP use after the discontinuation of denosumab, but further high-quality randomized trials are required to prove this.
- 4 September 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (36) , e50542
Open AccessPotent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis
Background: Denosumab cessation causes rebound bone turnover, fast bone loss, and an elevated risk of vertebral fractures. Pooled data about the fracture prevention efficacy of potent bisphosphonates (BPs) as sequential therapy have been lacking to counteract this risk. Methods: This systematic review and meta-analysis was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. PubMed, Scopus, the Cochrane Library, and ClinicalTrials.gov were searched from the beginning through May 1, 2026. Included studies comprised adults with osteoporosis or low bone mass who discontinued denosumab and subsequently received potent BP therapy, defined as alendronate or zoledronic acid, compared with no subsequent antiresorptive therapy or a selective estrogen receptor modulator (SERM). Random-effects meta-analyses were performed using the Mantel–Haenszel method to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). Prespecified subgroup analyses were conducted based on comparator type. The Grading of Recommendations Assessment, Development and Evaluation assessment method was applied to assess the certainty of the evidence. Results: Six studies were included; 683 participants contributed to the primary incident vertebral fracture analysis. Potent BP therapy was linked to a considerable reduction in incident vertebral fractures (RR = 0.29; 95% CI: 0.14–0.59; 71% relative risk reduction), multiple vertebral fractures (RR = 0.08; 95% CI: 0.01–0.43; 92% relative risk reduction), and clinical vertebral fractures (RR = 0.18; 95% CI: 0.07–0.49; 82% relative risk reduction). The protective effect was driven mainly by comparisons with no subsequent therapy, while comparisons with SERM therapy were limited and not statistically significant. There was no statistically significant reduction in any fracture (RR = 0.35; 95% CI: 0.10–1.24) or non-vertebral fracture (RR = 0.43; 95% CI: 0.07–2.64). Overall certainty of evidence was low to very low, mainly due to the observational nature of most included studies and imprecision in several outcomes. Conclusion: Potent BP therapy was related to decreased vertebral fracture risk after denosumab termination, particularly when compared with no subsequent therapy. Evidence versus SERM comparators was limited and inconclusive. The results are in agreement with the present clinical guideline recommendations for sequential BP use after the discontinuation of denosumab, but further high-quality randomized trials are required to prove this.
- Open Access
- 6 August 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1)
Comment on “Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis” by Chen et al.
Highlights: METS-IR and SIRI associations with RCC remain observational. Diagnostic intensity and repeat-attendance selection may influence estimates. Trajectory findings do not establish reversibility of RCC risk.
- 6 August 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1)
Open AccessComment on “Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis” by Chen et al.
Highlights: METS-IR and SIRI associations with RCC remain observational. Diagnostic intensity and repeat-attendance selection may influence estimates. Trajectory findings do not establish reversibility of RCC risk.
- 22 July 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (4) , 89
Comment on “Characterization of individuals with skeletal dysplasia at a referral center in Brazil”
- 22 July 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (4) , 89
Comment on “Characterization of individuals with skeletal dysplasia at a referral center in Brazil”
- Open Access
- 14 July 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (11) , 14936-14937
Telesurgery reliability in robotic resection of pineal region germ cell tumors: multicenter 2026 5G-optics data on latency and oncologic control
- 14 July 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (11) , 14936-14937
Open AccessTelesurgery reliability in robotic resection of pineal region germ cell tumors: multicenter 2026 5G-optics data on latency and oncologic control